Welcome to our dedicated page for Cytokinetics SEC filings (Ticker: CYTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cytokinetics, Incorporated filings document a specialty cardiovascular biopharmaceutical company with common stock listed on the Nasdaq Global Select Market. Its 8-K reports cover financial results, corporate presentations, MYQORZO® regulatory approvals, clinical and regulatory disclosures, and material capital-structure events such as underwriting agreements for common stock offerings.
Proxy materials describe board elections, executive compensation, auditor ratification and equity plan amendments, including matters tied to the company’s employee stock purchase plan. Other filings address governance changes, risk disclosures, registered securities, exhibits and Inline XBRL cover-page data associated with Cytokinetics’ public-company reporting obligations.
FMR LLC reports beneficial ownership of 5,248,579.71 shares of Cytokinetics Inc. Common Stock, representing 3.9% of the class as of 06/30/2026. The filing (Amendment No. 8 to Schedule 13G/A) lists sole dispositive power for 5,248,579.71 shares and sole voting power of 5,220,899.42 shares. The report notes that one or more other persons may have rights to dividends or sale proceeds but that no other person holds more than 5% of the outstanding common stock. The filing is signed under a power of attorney and references an exhibit for a 13d-1(k)(1) agreement.
CYTOKINETICS INC EVP Research & Development Fady Ibraham Malik reported an exercise-and-sale transaction in company stock. He sold 3,500 shares of common stock in an open-market sale at $86.62 per share and exercised options to acquire 3,500 shares at $7.80 per share. Following these transactions, he directly holds 153,902 shares of common stock and 37,386 non-qualified stock options.
CYTK submitted a Form 144 notice to sell 24,500 shares of Common Stock via exercise of stock options, dated 07/07/2026, with sale method listed as Cash. The filing also lists five prior 10b5-1 sales of 3,500 shares each in April–June 2026.
Cytokinetics President & CEO Robert I. Blum reported an open-market sale of 7,500 shares of Cytokinetics common stock at $84.92 per share on July 1, 2026. After this sale, he directly holds 377,830 shares of common stock.
In addition to his direct holdings, there are indirect positions of 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust. These trust positions are reported as indirect ownership on the Form 4.
CYTOKINETICS INC executive Andrew Callos reported an option exercise paired with a sale of common stock. On July 1, 2026, he exercised options to acquire 15,000 shares of Common Stock at $23.26 per share, then sold 15,000 shares in an open-market transaction at an average price of $85.80 per share. Following these transactions, he directly owns 58,555 shares of Common Stock and holds 24,000 non-qualified stock options with a $23.26 exercise price expiring on March 31, 2031. The stock options referenced vest over four years, with an initial one-year cliff and monthly vesting thereafter, subject to continued employment.
CYTOKINETICS INC EVP and CFO Sung Lee reported an option exercise and related share sale. Lee exercised non-qualified stock options for 1,112 shares of common stock at $48.51 per share, then sold 1,112 shares in an open-market transaction at $87.79 per share.
Following these transactions, Lee directly holds 63,221 shares of common stock. The filing also shows 26,709 non-qualified stock options remaining outstanding with an exercise price of $48.51 per share and an expiration date of May 30, 2034, indicating a continuing equity stake alongside the sale.
Robert Blum filed a Form 144 reporting proposed sales and recent 10b5-1 transactions in CYTK common stock. The notice lists a proposed sale of 44,990 shares tied to an exercise of stock options on 07/01/2026 and 7,510 shares from Restricted Stock Units dated 03/14/2025. The filing also records completed 10b5-1 sales of 7,500 shares on each of 04/15/2026, 04/29/2026, 05/14/2026, 05/27/2026, and 06/15/2026, with the proceeds for each sale shown in the excerpt.
Cytokinetics EVP and CFO Sung Lee reported an exercise-and-sell transaction in company stock. On June 24, 2026, Lee exercised stock options to acquire a total of 38,730 shares of Cytokinetics common stock at strike prices of $48.51 and $44.36 per share, then sold 38,730 shares in an open-market sale at an average price of $82.30 per share. Following the sale, Lee directly owned 63,221 shares of Cytokinetics common stock.
CYTOKINETICS INC EVP and CFO Sung Lee reported a mix of option exercises and share sales. On June 29, 2026, Lee exercised options to acquire a total of 3,134 shares of common stock through multiple transactions at exercise prices of $44.36 and $48.51 per share. On the same date, Lee executed an open-market sale of 3,134 shares of common stock at $85.00 per share, effectively converting option-based compensation into cash while shifting exposure from options into owned shares.
CYTK filing reports an exercise of stock options for 9,503 shares on 06/29/2026 settled for cash. The filing also lists recent Rule 10b5-1 sales by Sung Lee: 6,695 shares on 06/26/2026 for $562,380, 38,730 shares on 06/24/2026 for $3,187,328.11, and 23,906 shares on 05/05/2026 for $1,837,766.45. The Form 144 records the planned resale after option exercise and lists prior sales under a 10b5-1 plan.